CompletedNCT06315283
TV-44749 comparison with olanzapine in schizophrenia
About this title
Read the official source — NCT06315283Medication studyAges 18–64Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Los Alamitos and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: March 20, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 153
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States, United Kingdom, Croatia, ...
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT06315283
- Official title
Show the full official title
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Los Alamitos, United States · Torrance, United States · Hollywood, United States
6 more locations
- Atlanta, United States
- Decatur, United States
- Marlton, United States
- Zagreb, Croatia
- Zamora, Spain
- Surrey, United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Teva Branded Pharmaceutical Products R&D LLC, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including TV-44749 and Oral olanzapine.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
